Reduction of NADPH-oxidase activity ameliorates the cardiovascular phenotype in a mouse model of Williams-Beuren Syndrome
about
The Williams-Beuren Syndrome-a window into genetic variants leading to the development of cardiovascular disease.High prevalence of cardiovascular risk factors in children and adolescents with Williams-Beuren syndromeNOX2 As a Target for Drug Development: Indications, Possible Complications, and Progress.Genome wide array-CGH and qPCR analysis for the identification of genome defects in Williams' syndrome patients in Saudi ArabiaFunctional and genetic characterization of two extremely rare cases of Williams-Beuren syndrome associated with chronic granulomatous disease.Altered reactivity of resistance vasculature contributes to hypertension in elastin insufficiency.Metabolic abnormalities in Williams-Beuren syndrome.Antioxidant Supplementation Modulates Age-Related Placental Bed Morphology and Reproductive Outcome in Mice.mTOR (Mechanistic Target of Rapamycin) Inhibition Decreases Mechanosignaling, Collagen Accumulation, and Stiffening of the Thoracic Aorta in Elastin-Deficient Mice.Deficient Circumferential Growth Is the Primary Determinant of Aortic Obstruction Attributable to Partial Elastin Deficiency.7q11.23 dosage-dependent dysregulation in human pluripotent stem cells affects transcriptional programs in disease-relevant lineages.Heterozygous deletion of the Williams-Beuren syndrome critical interval in mice recapitulates most features of the human disorder.Epigallocatechin-3-gallate improves cardiac hypertrophy and short-term memory deficits in a Williams-Beuren syndrome mouse model.
P2860
Q34154469-8DC13390-C932-4E72-A414-FE3DD77F310EQ35780528-C728FA43-7462-4D3B-BB06-D13C02C456A4Q35985407-FA0D70E4-5983-4439-9C15-BA35D90B0A6FQ37169363-FD8D1819-DD93-4BE9-B547-C9F7568C4C25Q37186009-80F923ED-68EF-47E0-8094-E70B0902E30CQ37629251-63B3E082-6A0A-49BE-A19E-23A53EA1F037Q41461696-73B4C6EA-EF7B-4550-AD06-0EBED4D86EE9Q46700129-015ACC69-DA2E-4C39-A6E0-24C8ABC04D42Q47813818-4DD58B64-FC38-40F8-B825-FDD63AAADF94Q47956266-A5F1CBB1-3A9E-424F-B6CA-23FC82DC8DCAQ48246014-0C6C9CC2-DCBE-4DB7-BFE9-ABCA8ABE5956Q48658363-11C62325-E889-4862-94A3-5A6D3CC2D0ACQ53431257-91E453A2-D3CE-4C51-8FB8-146B597B1B58
P2860
Reduction of NADPH-oxidase activity ameliorates the cardiovascular phenotype in a mouse model of Williams-Beuren Syndrome
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Reduction of NADPH-oxidase act ...... el of Williams-Beuren Syndrome
@ast
Reduction of NADPH-oxidase act ...... el of Williams-Beuren Syndrome
@en
Reduction of NADPH-oxidase act ...... el of Williams-Beuren Syndrome
@nl
type
label
Reduction of NADPH-oxidase act ...... el of Williams-Beuren Syndrome
@ast
Reduction of NADPH-oxidase act ...... el of Williams-Beuren Syndrome
@en
Reduction of NADPH-oxidase act ...... el of Williams-Beuren Syndrome
@nl
prefLabel
Reduction of NADPH-oxidase act ...... el of Williams-Beuren Syndrome
@ast
Reduction of NADPH-oxidase act ...... el of Williams-Beuren Syndrome
@en
Reduction of NADPH-oxidase act ...... el of Williams-Beuren Syndrome
@nl
P2093
P2860
P3181
P1433
P1476
Reduction of NADPH-oxidase act ...... el of Williams-Beuren Syndrome
@en
P2093
Carolina Sánchez-Rodríguez
Julián Nevado
Luis A Pérez-Jurado
Maria Segura-Puimedon
Mathilde Coustets
Mauricio Menacho-Márquez
Uta Francke
Verena Terrado
Victoria Campuzano
P2860
P304
P3181
P356
10.1371/JOURNAL.PGEN.1002458
P407
P577
2012-02-01T00:00:00Z